Press Release Cardiawave appoints Olivier Pierron as its Chief Executive Officer Apr 16, 2024 HeleneCardiawave 0
Press Release Cardiawave annonce la nomination d’Olivier Pierron en tant que Directeur Général Apr 16, 2024 HeleneCardiawave 0
Press Release Cardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis at the 73rd Annual Conference of the ACC – April 6–8, 2024, Atlanta (GA) Apr 5, 2024 HeleneCardiawave 0
Press Release Cardiawave présentera les résultats de suivi à 30 jours de son étude pivot « Valvosoft® Pivotal Study » pour le traitement de la sténose valvulaire aortique sévère symptomatique à la 73ème Conférence annuelle de l’ACC – 6-8 avril 2024 Apr 5, 2024 HeleneCardiawave 0
About Us Les fondateurs de Cardiawave lauréats du Palmarès des Inventeurs 2024 de Le Point! Mar 7, 2024 HeleneCardiawave 0
EventsCardiawave attended the CNRS Roundtable at Vivatech 2023 – June 14 – Paris Jun 13, 2023 © CNRS READ MORE
EventsCardiawave has secured the 2nd position among 50 exceptional participants for the prestigious John DeHann Foundation Award – May 15 – Paris Jun 8, 2023 © Cardiovascular News READ MORE
Scientific PublicationsSystematic brain magnetic resonance imaging and safety evaluation of non-invasive ultrasound therapy for patients with severe symptomatic aortic valve stenosis May 24, 2023 READ MORE
EventsCardiawave has been selected to participate to the Jon DeHaan Foundation Award Competition during EuroPCR Innovators’ Day – May 15 – Paris May 11, 2023 READ MORE
EventsCardiawave will participate in the 2nd edition of the HIFUture symposium – Apr. 21 – Lyon Apr 20, 2023 READ MORE
Press Release Cardiawave appoints Olivier Pierron as its Chief Executive Officer Apr 16, 2024 HeleneCardiawave 0
Press Release Cardiawave annonce la nomination d’Olivier Pierron en tant que Directeur Général Apr 16, 2024 HeleneCardiawave 0
Press Release Cardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis at the 73rd Annual Conference of the ACC – April 6–8, 2024, Atlanta (GA) Apr 5, 2024 HeleneCardiawave 0
Press Release Cardiawave présentera les résultats de suivi à 30 jours de son étude pivot « Valvosoft® Pivotal Study » pour le traitement de la sténose valvulaire aortique sévère symptomatique à la 73ème Conférence annuelle de l’ACC – 6-8 avril 2024 Apr 5, 2024 HeleneCardiawave 0
About Us Les fondateurs de Cardiawave lauréats du Palmarès des Inventeurs 2024 de Le Point! Mar 7, 2024 HeleneCardiawave 0